These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 18394961)

  • 21. Inhibition of class I phosphoinositide 3-kinase activity impairs proliferation and triggers apoptosis in acute promyelocytic leukemia without affecting atra-induced differentiation.
    Billottet C; Banerjee L; Vanhaesebroeck B; Khwaja A
    Cancer Res; 2009 Feb; 69(3):1027-36. PubMed ID: 19176369
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Selective PI3Kδ inhibitors, a review of the patent literature.
    Norman P
    Expert Opin Ther Pat; 2011 Nov; 21(11):1773-90. PubMed ID: 22017414
    [TBL] [Abstract][Full Text] [Related]  

  • 23. PI3K inhibitors for cancer treatment: where do we stand?
    Maira SM; Stauffer F; Schnell C; García-Echeverría C
    Biochem Soc Trans; 2009 Feb; 37(Pt 1):265-72. PubMed ID: 19143644
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Discovery of new aminopyrimidine-based phosphoinositide 3-kinase beta (PI3Kβ) inhibitors with selectivity over PI3Kα.
    Kim J; Hong S; Hong S
    Bioorg Med Chem Lett; 2011 Dec; 21(23):6977-81. PubMed ID: 22030027
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Phosphatidylinositol-3-kinase/Akt signaling pathway and kidney cancer, and the therapeutic potential of phosphatidylinositol-3-kinase/Akt inhibitors.
    Porta C; Figlin RA
    J Urol; 2009 Dec; 182(6):2569-77. PubMed ID: 19836781
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The PI3K/Akt/mTOR pathway in innate immune cells: emerging therapeutic applications.
    Weichhart T; Säemann MD
    Ann Rheum Dis; 2008 Dec; 67 Suppl 3():iii70-4. PubMed ID: 19022819
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Rho kinase as a therapeutic target in the treatment of asthma and chronic obstructive pulmonary disease.
    Fernandes LB; Henry PJ; Goldie RG
    Ther Adv Respir Dis; 2007 Oct; 1(1):25-33. PubMed ID: 19124345
    [TBL] [Abstract][Full Text] [Related]  

  • 28. In vivo antitumor activity of MEK and phosphatidylinositol 3-kinase inhibitors in basal-like breast cancer models.
    Hoeflich KP; O'Brien C; Boyd Z; Cavet G; Guerrero S; Jung K; Januario T; Savage H; Punnoose E; Truong T; Zhou W; Berry L; Murray L; Amler L; Belvin M; Friedman LS; Lackner MR
    Clin Cancer Res; 2009 Jul; 15(14):4649-64. PubMed ID: 19567590
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Characterization of PI3K class IA isoforms with regulatory subunit p55alpha using a scintillation proximity assay.
    Van Aller GS; Carson JD; Fernandes C; Lehr R; Sinnamon RH; Kirkpatrick RB; Tummino PJ; Luo L
    Anal Biochem; 2008 Dec; 383(2):311-5. PubMed ID: 18814837
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Design and synthesis of phenethyl benzo[1,4]oxazine-3-ones as potent inhibitors of PI3Kinasegamma.
    Lanni TB; Greene KL; Kolz CN; Para KS; Visnick M; Mobley JL; Dudley DT; Baginski TJ; Liimatta MB
    Bioorg Med Chem Lett; 2007 Feb; 17(3):756-60. PubMed ID: 17095227
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Targeting RAS and PI3K in lung cancer.
    Downward J
    Nat Med; 2008 Dec; 14(12):1315-6. PubMed ID: 19057554
    [No Abstract]   [Full Text] [Related]  

  • 32. Down-regulation of class II phosphoinositide 3-kinase alpha expression below a critical threshold induces apoptotic cell death.
    Elis W; Triantafellow E; Wolters NM; Sian KR; Caponigro G; Borawski J; Gaither LA; Murphy LO; Finan PM; Mackeigan JP
    Mol Cancer Res; 2008 Apr; 6(4):614-23. PubMed ID: 18403640
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Vanillin suppresses metastatic potential of human cancer cells through PI3K inhibition and decreases angiogenesis in vivo.
    Lirdprapamongkol K; Kramb JP; Suthiphongchai T; Surarit R; Srisomsap C; Dannhardt G; Svasti J
    J Agric Food Chem; 2009 Apr; 57(8):3055-63. PubMed ID: 19368348
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Role of phosphoinositide 3-kinase p110 delta in TLR4- and TLR9-mediated B cell cytokine production and differentiation.
    Dil N; Marshall AJ
    Mol Immunol; 2009 Jun; 46(10):1970-8. PubMed ID: 19362372
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Phosphatidylinositol 3-kinase gamma is a critical mediator of myocardial ischemic and adenosine-mediated preconditioning.
    Ban K; Cooper AJ; Samuel S; Bhatti A; Patel M; Izumo S; Penninger JM; Backx PH; Oudit GY; Tsushima RG
    Circ Res; 2008 Sep; 103(6):643-53. PubMed ID: 18688045
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Fine tuning the immune response with PI3K.
    Fruman DA; Bismuth G
    Immunol Rev; 2009 Mar; 228(1):253-72. PubMed ID: 19290933
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Aerosolized phosphoinositide 3-kinase gamma/delta inhibitor TG100-115 [3-[2,4-diamino-6-(3-hydroxyphenyl)pteridin-7-yl]phenol] as a therapeutic candidate for asthma and chronic obstructive pulmonary disease.
    Doukas J; Eide L; Stebbins K; Racanelli-Layton A; Dellamary L; Martin M; Dneprovskaia E; Noronha G; Soll R; Wrasidlo W; Acevedo LM; Cheresh DA
    J Pharmacol Exp Ther; 2009 Mar; 328(3):758-65. PubMed ID: 19056934
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Allergic airway hyperresponsiveness, inflammation, and remodeling do not develop in phosphoinositide 3-kinase gamma-deficient mice.
    Takeda M; Ito W; Tanabe M; Ueki S; Kato H; Kihara J; Tanigai T; Chiba T; Yamaguchi K; Kayaba H; Imai Y; Okuyama K; Ohno I; Sasaki T; Chihara J
    J Allergy Clin Immunol; 2009 Apr; 123(4):805-12. PubMed ID: 19232703
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Targeting the PI3K p110alpha isoform inhibits medulloblastoma proliferation, chemoresistance, and migration.
    Guerreiro AS; Fattet S; Fischer B; Shalaby T; Jackson SP; Schoenwaelder SM; Grotzer MA; Delattre O; Arcaro A
    Clin Cancer Res; 2008 Nov; 14(21):6761-9. PubMed ID: 18980969
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Opioids and the management of chronic severe pain in the elderly: consensus statement of an International Expert Panel with focus on the six clinically most often used World Health Organization Step III opioids (buprenorphine, fentanyl, hydromorphone, methadone, morphine, oxycodone).
    Pergolizzi J; Böger RH; Budd K; Dahan A; Erdine S; Hans G; Kress HG; Langford R; Likar R; Raffa RB; Sacerdote P
    Pain Pract; 2008; 8(4):287-313. PubMed ID: 18503626
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.